Infection Prevention Enhanced Monitoring Report July 2023





Quality, Safety and Experience Committee

Current rate per 100,000 population by Health Board April-June 23




	C. difficile	MRSA bacteraemia	MSSA bacteraemia	E. coli bacteraemia	Klebsiella sp bacteraemia	P. aeruginosa bacteraemia
Aneurin Bevan UHB	31.6	1.34	13.45	61.86	20.84	4.03
Betsi Cadwaladr UHB	40.03	0	25.16	71.48	18.3	5.72
Cardiff and Vale UHB	23.92	1.59	34.28	66.17	27.9	2.39
Cwm Taf Morgannwg UHB	23.25	1.79	31.29	102.82	24.14	2.68
Hywel Dda UHB	39.22	1.03	27.86	114.55	25.8	10.32
Powys THB	12.09	0	0	6.05	0	0
Swansea Bay UHB	51.44	3.09	38.06	75.1	24.69	7.2
Velindre NHST						
Wales	33.75	1.27	26.14	76.52	22.33	4.95

НВ	C. difficile	E. coli	Klebsiella	P. aeruginosa	S. aureus
Aneurin Bevan UHB	12	30	7	1	10
Betsi Cadwaladr UHB	21	48	16	2	18
Cardiff and Vale UHB	10	26	8	0	19
Cwm Taf Morgannwg UHB	8	37	10	1	15
Hywel Dda UHB	12	37	4	4	14
Swansea Bay UHB	20	25	6	4	13

Clostridioides difficile (C. diff) Trajectory Figures







HCAI Dashboard




C.diff case numbers across HB






Targeted approach







C. diff Improvement Measures



	Total count	CO* count	HO** count	% HO***	Total rate per 1,000 hospital admissions	Total rate per 100,000 population
2023/24	38	22	16	42%	2.98	39.22
April 2023	12	5	7	58%	3.03	37.57
May 2023	14	8	6	43%	3.19	42.41
June 2023	12	9	3	25%	2.74	37.57

- Continuing compliance for 20% reduction trajectory
- Post infection review (root cause analysis) process embedded
- Scrutiny meetings continue
- Improved medical engagement needs to be sustained
- Medication chart Proton Pump Inhibitor awareness stickers successfully trialled in PPH – now utilised on all sites
- C.diff stickers for medical notes currently being printed
- Faecal Microbiota Transplant (FMT) service gaining momentum
- C.diff internal review circulated to IPSSG members forwarded to Welsh Government
- Working individually and at cluster level with GP's raising awareness of C.diff symptoms, antimicrobial stewardship and latest NICE treatment guidelines continues.
- Successful trial of new cleaning product Diff X (paracetic acid compound) in BGH

Recommendation



For the Quality, Safety and Experience Committee to note the update provided and take assurance from the improvement measures.



DIOGEL | CYNALIADWY | HYGYRCH | CAREDIG SAFE | SUSTAINABLE | ACCESSIBLE | KIND

